Podcasts about Eli Lilly

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's Headlines: House Democrats want no-longer-Prince Andrew to testify about his ties to Jeffrey Epstein. Meanwhile, Nancy Pelosi announced her retirement, with California Sen. Scott Wiener emerging as the establishment pick — though AOC's ex–campaign manager Saikat Chakrabarti plans to run too. A federal judge ruled again that Trump must fully fund SNAP benefits by today, but the DOJ is appealing. Trump also struck a deal with Eli Lilly and Novo Nordisk to cap Ozempic-style drugs at $50 for Medicare and Medicaid patients next year. In smaller but iconic justice news, the D.C. “sandwich guy” who threw a sub at an ICE agent was found not guilty of assault. The Heritage Foundation is in “open revolt” after its president defended Tucker Carlson for hosting white supremacist Nick Fuentes. Staffers, including members of its antisemitism task force, have quit. Meanwhile, FIFA announced a mysterious new “peace prize” ahead of the World Cup draw in D.C., which insiders say Trump demanded after missing out on a Nobel. And Tesla's board is set to hand Elon Musk a $1 trillion compensation deal. Resources/Articles mentioned in this episode: Politico: House Oversight Democrats call on embattled royal Andrew Windsor to testify - Live Updates Politico: California's attorney general endorses Scott Wiener to succeed Pelosi NYT: Judge Orders Trump Administration to Fully Fund SNAP Benefits This Month WaPo: Trump, long fixated on ‘fat drug,' announces deal to lower its price WaPo: Jury finds D.C. ‘sandwich guy' not guilty of assaulting officer WaPo: Heritage staff in open revolt over leader's defense of Tucker Carlson Axios: Trump teased as possible first FIFA Peace Prize winner CNBC: Elon Musk expected to prevail in Tesla shareholder vote over CEO's $1 trillion pay plan  Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration's plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk's $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk's history of exceeding investor expectations. Plus, U.S. airlines are beginning to cancel flights to manage shutdown-strained staffing of air traffic controllers, and Warren Buffett issued a warning on AI.  Dr. Mehmet Oz - 21:43Walter Isaacson - 38:56 In this episode:Dr. Mehmet Oz, @DrOzJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tesla shareholders put Elon Musk on the path to becoming a trillionaire. Meta is earning a fortune from fraudulent ads – host Carmel Crimmins discusses our exclusive. Reuters also reveals Google's plan to build an AI centre on a tiny Australian Indian Ocean island. And Novo Nordisk and Eli Lilly cut a deal with Trump to slash weight-loss drug prices.     Sign up for the Reuters Econ World newsletter here. Listen to the Reuters Econ World podcast here. Find the Recommended Read here. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

Mehr Infos zum Kreditangebot von unserem Partner Scalable Capital findet ihr hier: https://de.scalable.capital/credit. Zalando und DHL liefern, Börse jubelt. Datadog überzeugt. Eli Lilly und Novo Nordisk haben Deal mit Trump. Duolingo will wachsen und nicht profitabel werden, Börse schimpft. Marvell wurde fast gekauft, HelloFresh hat Short-Attacke und Take-Two verschiebt GTA VI wieder. Lemonade (WKN: A2P7Z1) will das OpenAI der Versicherungswelt werden. Klappt das? Quantencomputing-Aktien waren an der Börse in den letzten Monaten Highflyer. Wie funktioniert die Technologie, wie funktioniert der Markt und wie erkennt man vertrauensvolle Firmen? Daniel Volz von Kipu Quantum klärt auf. Diesen Podcast vom 07.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Gear up, freedom fighters—@intheMatrixxx and @shadygrooove charge into Season 7, Episode 212, "Trump Makes Announcement; Erika Kirk 1st Interview," dismantling deep-state distractions while spotlighting President Trump's powerhouse move to slash obesity drug prices to $149 a month for many Americans through deals with Eli Lilly and Novo Nordisk. As relentless exposers of globalist schemes, the hosts dissect this win for everyday patriots against Big Pharma greed, then pivot to Erika Kirk's raw, faith-fueled first TV sit-down since her husband Charlie Kirk's tragic assassination, where she honors his Turning Point USA legacy and stands firm amid loss. With sharp live breakdowns and unyielding America-First analysis, they equip you to reject establishment spin and defend sovereignty. The truth is learned, never told—the constitution is your weapon. Tune in at noon-0-five Eastern LIVE to stand with Trump! Trump, drug prices, Erika Kirk, Charlie Kirk, America First, MG Show, @intheMatrixxx, @shadygrooove, Turning Point USA, Big Pharma, patriotic intel mgshow_s7e212_trump_makes_announcement_erika_kirk_1st_interview Tune in weekdays at 12pm ET / 9am PST, hosted by @InTheMatrixxx and @Shadygrooove. Catch up on-demand on https://rumble.com/mgshow or via your favorite podcast platform. Where to Watch & Listen Live on https://rumble.com/mgshow https://mgshow.link/redstate X: https://x.com/inthematrixxx Backup: https://kick.com/mgshow PODCASTS: Available on PodBean, Apple, Pandora, and Amazon Music. Search for "MG Show" to listen. Engage with Us Join the conversation on https://t.me/mgshowchannel and participate in live voice chats at https://t.me/MGShow. Social Follow us on X: @intheMatrixxx https://x.com/inthematrixxx @ShadyGrooove https://x.com/shadygrooove Follow us on YouTube: ShadyGrooove https://www.youtube.com/c/TruthForFreedom Support the show: Fundraiser: https://givesendgo.com/helpmgshow Donate: https://mg.show/support Merch: https://merch.mg.show MyPillow Special: Use code MGSHOW at https://mypillow.com/mgshow for savings! Wanna send crypto? Bitcoin: bc1qtl2mftxzv8cxnzenmpav6t72a95yudtkq9dsuf Ethereum: 0xA11f0d2A68193cC57FAF9787F6Db1d3c98cf0b4D ADA: addr1q9z3urhje7jp2g85m3d4avfegrxapdhp726qpcf7czekeuayrlwx4lrzcfxzvupnlqqjjfl0rw08z0fmgzdk7z4zzgnqujqzsf XLM: GAWJ55N3QFYPFA2IC6HBEQ3OTGJGDG6OMY6RHP4ZIDFJLQPEUS5RAMO7 LTC: ltc1qapwe55ljayyav8hgg2f9dx2y0dxy73u0tya0pu All Links Find everything on https://linktr.ee/mgshow Intermission Music Lemurian Shores (with Lucentia) (~432 Hz) by Spheriá | https://soundcloud.com/spheriamusic Music promoted by https://www.chosic.com/free-music/all/ Creative Commons CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0/

A federal judge ruled Thursday that the Trump administration must fully fund SNAP benefits amid the government shutdown, giving officials until Friday to secure the money. Meanwhile, as the shutdown continues, 40 major U.S. airports—including Los Angeles International, John F. Kennedy International, and Chicago O'Hare—will face a 10 percent reduction in flights starting Friday.President Donald Trump, just one day after Supreme Court arguments on his sweeping global tariffs in a case he called “one of the most important cases in the history of our country,” is doubling down—emphasizing that his tariff threats against Beijing were a national security lifeline that forced Xi Jinping to the negotiating table. The president is also set to meet with the leaders of all five Central Asian countries Thursday night as the United States works to expand its influence in a region increasingly courted by China.Trump also announced new agreements to expand access to and reduce the cost of weight loss drugs. The deals with pharmaceutical companies Novo Nordisk and Eli Lilly will broaden coverage for Medicare and Medicaid recipients and lower the prices paid by the federal government.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

President Trump strikes a groundbreaking deal with Eli Lilly and Novo Nordisk to slash prices on popular weight-loss drugs for Medicare, Medicaid, and out-of-pocket patients. Nov 6th 2025 --- Please Like, Comment and Follow 'The Ray Appleton Show' on all platforms: --- 'The Ray Appleton Show’ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- 'The Ray Appleton Show’ Weekdays 11 AM -2 PM Pacific on News/Talk 580 AM & 105.9 KMJ | Website | Facebook | Podcast | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

President Donald Trump announced a major initiative aimed at lowering the cost of popular weight loss drugs in the U.S. Pres. Trump unveiled deals with Eli Lilly and Novo Nordisk to reduce prices on Wegovy (Novo Nordisk), Zepbound (Eli Lilly) and potential inclusion of Ozempic, primarily a diabetes drug also used for weight loss. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

AI and speculative stocks slide again. The FAA is cutting flights by 10% at 40 major airports due to the government shutdown.  And President Trump announces deals with Eli Lilly and Novo Nordisk to cut the cost of weight loss drugs.    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen?

Learn more about your ad choices. Visit megaphone.fm/adchoices

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. What it means for the space, and how it could change medicare coverage of the weight loss drugs.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to Daily Global #News from Grecian Echoes WNTN 1550 AM -  Democrats won the races in the first major elections since Trump became president - Trump is negotiating a deal with Eli Lilly and Novo Nordisk that would lower obesity drug price - The government shutdown has entered its 36th day, setting a new record

Many of the top stories of 2025 are currently being written. We're on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duke it out over the right to acquire glittery obesity startup Metsera. In the latest development, Pfizer raised its original bid of around $7.27 billion to about $8.1 billion on Monday—only to be usurped again by the indefatigable Novo, which upped its own bid to a cool $10 billion.  Meanwhile, the unprecedented drama in the uppermost ranks of the FDA—another top story of 2025—continues as CDER Director George Tidmarsh exits the agency. Tidmarsh reportedly resigned Sunday after being placed on administrative leave amid an investigation into his “personal conduct” at the agency. On Monday, however, Tidmarsh told Endpoints News that he was “second-guessing” his decision.  Speaking of the FDA, the regulator appears to have done its own 180—on uniQure's investigational gene therapy for Huntington's disease, three-year data from which sent the biotech's stock into the stratosphere just five weeks ago. Despite previous agreements on protocols and statistical analyses, the agency “no longer agrees” that Phase I/II data for AMT-130 are adequate to provide primary evidence for the application, uniQure said, throwing the timeline for the BLA into question.  Another gene therapy player, Sarepta Therapeutics, took a hit this week, as two of its Duchenne muscular dystrophy drugs, Vyondys 53 and Amondys 45, failed a confirmatory trial. Sarepta still plans to file for full approval of the two exon-skipping therapies, however, based on what it called “encouraging trends” in efficacy. Finally, on the genetic medicine front, CBER director Vinay Prasad teased an upcoming paper that will detail the regulator's thinking and a new approach to gene editing approvals.  On top of all that, Q3 earnings continue to roll in, with Pfizer, Eli Lilly, Vertex, Bristol Myers Squibb, AbbVie, and more reporting results.  One more thing: Have you ever wanted to know more about the inner workings of the Biogen-Eisai Alzheimer's partnership? Check out this profile on BioSpace 40 under 40 honoree Neena Bitritto-Garg, Eisai alum and current CEO of Ensho Therapeutics. 

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of The Medical Alley Podcast, we're recognizing Alzheimer's Awareness Month with three special guests: Dr. Brandy Matthews (VP, Global & US Medical Affairs, Alzheimer's Disease at Eli Lilly and Company), Dr. Ronald Petersen (Neurologist, Mayo Clinic Alzheimer's Disease Research Center), and Robert Freeman (VP, Public Policy, Alzheimer's Association, MN-ND Chapter).In the discussion, we break down what Alzheimer's Disease is, how it's diagnosed, the latest innovations in research and treatments, and what the future of Alzheimer's care could look like.Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

Het Amerikaanse farmaconcern Eli Lilly gaat in Katwijk, vlakbij Leiden, een fabriek bouwen voor de productie van zijn medicijnen. Met dit project is een investering van €2,6 mrd gemoeid en de fabriek zal werk bieden aan vijfhonderd mensen. Dat heeft de onderneming maandagmiddag bekendgemaakt. Met redacteur Thieu Vaessen bespreken we de plannen en zeker ook waarom voor de regio Leiden is gekozen. Lees: Farmaconcern Eli Lilly investeert €2,6 mrd in nieuwe fabriek in Nederland ABN Amro grijpt in bij zijn duurzaamheidsteam. De bank heeft een adviesaanvraag ingediend om bijna zeventig van de vierhonderd duurzaamheidsexperts te ontslaan. Het is een volgende stap in een eerder ingezette reorganisatie. Redacteur Mathijs Rotteveel vertelt waarom en wat dat betekent voor de duurzaamheidsambities. Lees: ABN Amro reorganiseert zijn duurzaamheidsteam Nu de Utrechtse drinkwatervoorziening minimaal vier dagen plat ligt door een besmetting, begint de provincie de pijn te voelen. Drinkwaterbedrijf Vitens spreekt van een incidentele vervuiling. Grote bedrijven en ziekenhuizen nemen eigen maatregelen bij verstoring van de watervoorziening. Collega Evi Timp sprak met het waterbedrijf en getroffen organisaties en legt uit wat er aan de hand is en wat de impact is. Redactie: Nelleke van der Heiden en Floyd Bonder Presentatie: Floyd Bonder See omnystudio.com/listener for privacy information.

Dave and Brandon cover more of the winners and losers from the Q3 2025 earnings season

Warren Buffett heeft er niet echt zin meer in. Zijn Berkshire Hathaway blijft maar aandelen verkopen. Al drie jaar lang verkoopt hij meer, dan dat ie koopt. Zijn cashberg blijft maar groeien en tikt een nieuw record aan: hij heeft nu meer dan 381 miljard dollar achter de hand. Om aan te geven hoe krankzinnig veel dat is. Met dat geld kan je Ahold Delhaize, Prosus, Heineken, ING én Universal Music Group kopen. Deze aflevering kijken we of het terecht is dat Buffett maar niks koopt. Als hij geen kansen ziet, moet jij dan wel kopen? Ook hebben we het over modellen. Over auto's om precies te zijn. Auto-aandelen hadden er vandaag wél zin in. De vrees dat er een chiptekort ontstaat (door de ruzie tussen Nederland en China) is voor nu weg. Alleen, voor hoe lang?Verder bespreken we de jaarrekening van Ebusco. Dat ziet er niet goed uit, de accountant vond foutjes. Ook gaat het over de kwartaalcijfers PostNL en de ceo van Ryanair. Die is helemaal klaar met de Britse minister van Financiën. Deze aflevering gaat ook over Nvidia. Dat mag toch niet z'n meest geavanceerde chip verkopen in China. See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating advancements and strategic movements that are shaping the landscape of drug development and patient care.Starting with a significant milestone in precision oncology, China has approved its first EGFR-targeted antibody-drug conjugate. This approval marks a pivotal moment in the industry's shift towards targeted therapies, which promise more precise treatment options with potentially fewer side effects than traditional chemotherapy. Targeted therapies are at the forefront of personalized medicine, where treatments are tailored to individual genetic profiles, offering hope for more effective cancer care.In the realm of HIV prevention, Gilead Sciences has reported impressive sales for its new long-acting pre-exposure prophylaxis medication, Yetztugo. Since its launch in June 2025, Yetztugo has generated $54 million in U.S. sales, underscoring the demand for long-term HIV prevention solutions. This development is part of Gilead's broader strategy to strengthen its HIV franchise as it advances its pipeline with promising candidates like GS-3242 alongside lenacapavir. The aim is to develop treatments that require less frequent dosing, which could significantly improve patient adherence and outcomes. Despite challenges within its HIV portfolio and declining Veklury sales, Gilead Sciences is actively seeking growth opportunities through strategic partnerships and pipeline advancements—an essential approach for navigating patent cliffs while sustaining long-term growth.On the financial front, AbbVie has increased its revenue forecast by $400 million to a staggering $60.9 billion, driven by robust sales from its immunology drugs Skyrizi and Rinvoq. These treatments address chronic inflammatory conditions like psoriasis and rheumatoid arthritis, reflecting AbbVie's strong positioning in this therapeutic area despite competitive pressures. AbbVie continues to report strong earnings from Skyrizi and Rinvoq, reinforcing its dominance in the immunology market and highlighting the profitable nature of successful biologics in treating chronic inflammatory diseases.Biogen continues to bolster its multiple sclerosis franchise by focusing on both legacy treatments and new product launches. This strategy highlights the importance of balancing innovation with lifecycle management to maintain market strength against generic competition—a common challenge in the industry.Meanwhile, the American Academy of Pediatrics has taken a cautious stance by not endorsing leucovorin for autism treatment due to insufficient evidence. This decision emphasizes the critical need for rigorous, evidence-based practices in developing clinical guidelines for complex disorders like autism.Internationally, CSL Seqirus has partnered with Saudi Arabia to supply cell-based influenza vaccines and support local production capabilities. This move aligns with global efforts to enhance pandemic preparedness and healthcare resilience through local manufacturing initiatives.The volatile nature of the biotech sector is evident with reports of 16 companies ceasing operations in 2025 due to high R&D costs and regulatory challenges. Despite these closures, such volatility opens doors for new innovations that could address unmet medical needs.Turning our attention to obesity treatment, Eli Lilly stands at a crucial juncture with its novel obesity medication, orforglipron. The company aims to make this weight loss pill accessible while maintaining financial viability for future R&D—a balancing act faced by many pharmaceutical companies as they strive to deliver affordable yet innovative treatments amid growing global health concerns. However, not all R&D efforts reach fruition. Eli Lilly has decided to discontinue its mid-stage program Support the show

Warren Buffett heeft er niet echt zin meer in. Zijn Berkshire Hathaway blijft maar aandelen verkopen. Al drie jaar lang verkoopt hij meer, dan dat ie koopt. Zijn cashberg blijft maar groeien en tikt een nieuw record aan: hij heeft nu meer dan 381 miljard dollar achter de hand. Om aan te geven hoe krankzinnig veel dat is. Met dat geld kan je Ahold Delhaize, Prosus, Heineken, ING én Universal Music Group kopen. Deze aflevering kijken we of het terecht is dat Buffett maar niks koopt. Als hij geen kansen ziet, moet jij dan wel kopen? Ook hebben we het over modellen. Over auto's om precies te zijn. Auto-aandelen hadden er vandaag wél zin in. De vrees dat er een chiptekort ontstaat (door de ruzie tussen Nederland en China) is voor nu weg. Alleen, voor hoe lang?Verder bespreken we de jaarrekening van Ebusco. Dat ziet er niet goed uit, de accountant vond foutjes. Ook gaat het over de kwartaalcijfers PostNL en de ceo van Ryanair. Die is helemaal klaar met de Britse minister van Financiën. Deze aflevering gaat ook over Nvidia. Dat mag toch niet z'n meest geavanceerde chip verkopen in China. See omnystudio.com/listener for privacy information.

En el episodio de hoy, analizamos cómo prevaleció el Team Alcaldes en el más reciente pulso político entre la Gobernadora y la Legislatura. En el segundo bloque, abordamos la expansión histórica de Eli Lilly en Puerto Rico, una inversión multimillonaria que el gobierno celebra como una gran victoria económica. Más adelante, conversamos sobre Trump, el filibusterismo y la estadidad, en medio del cierre del gobierno federal y la creciente incertidumbre política en Washington. Y para cerrar, un Patreon Exclusive con la designación de Josué Rivera al Banco de Desarrollo Económico — una movida que da mucho de qué hablar. En el chit chat discutimos el rant viral de Carlitos Bermúdez, la respuesta de Pablo José, y todo el contenido del fin de semana: Halloween, K-Pop Demons Hunters, Blippi, el velociraptor y el unicornio más viral del mes. Octubre cierra caliente y viene noviembre, el mejor mes para entrar al Patreon — con preventa y descuentos exclusivos de los PPP Awards. Si fueras integrante de nuestro Patreon, hubieras escuchado este episodio ayer. Únete ahora en patreon.com/puestospalproblema! Presentado por AeroNet – Nuevo plan GigaFaster Essential: 200/50 Mbps por $99 al mes, con router WiFi incluido.

Christine Short and Scott Zari cover Eli Lilly (LLY) earnings and the future of GLP-1 drugs. Christine emphasizes the global demand for these drugs, as evidenced by higher international revenue, and what a daily oral GLP-1 pill could do for the company. Scott looks at Eli Lilly's market share in the weight loss sector, calling it a “two horse race” between them and Novo Nordisk (NVO).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

1. Sigue el “excelente ambiente laboral” dentro del PNP. Del impuesto al inventario a la reforma contributiva. TRS vuelve al ataque. 2. Nuevas señales de crisis financiera de New Fortress. Busca mecanismo similar a la quiebra en Inglaterra 3. Vista pública ayer en la Cámara no contestó las interrogantes sobre la crisis de liquidez financiera del sistema eléctrico 4. Gobernadora dice hay hasta tres compañías interesadas en sustituir a LUMA 5. Gobierno vuelve a cambiar su versión. Ahora director de OGP contradice a la gobernadora y dice hay dinero para el PAN. 6. Federales acusan por esquema corrupto en el Departamento de Hacienda- Empleados y empresarios 7. Buena noticia: farmacéutica Eli Lilly construirá nueva planta en PR 8. Otra buena noticia: la reserva federal baja la tasa de interés 9. Converso con Eric González de Gibaro de Puerto Rico y su nuevo espectáculoSee omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action obesity medications, Zepbound and Mounjaro. Despite being removed from the CVS formulary, these drugs have achieved exceptional sales figures, reaching $10 billion in a single quarter. This success can be attributed to Lilly's innovative direct-to-consumer sales strategy, which exemplifies how modern marketing approaches can overcome traditional market barriers. Additionally, Eli Lilly's partnership with Walmart to expand access to Zepbound through retail pharmacy pickups exemplifies a strategic approach to enhancing patient access to crucial medications. By leveraging Walmart's extensive retail network, this collaboration facilitates easier access to obesity treatments—a significant public health challenge—enhancing both patient convenience and broadening market reach for Lilly's products. These achievements not only highlight the potential of strategic marketing but also underscore a growing demand for effective obesity treatments within the pharmaceutical industry.In another exciting development, Alnylam Pharmaceuticals has reported impressive sales figures for Amvuttra, a treatment for transthyretin amyloid cardiomyopathy. Surpassing analysts' expectations, this success signals a growing market for treatments targeting rare diseases and emphasizes the importance of strategic market expansion to reach underserved patient populations.Meanwhile, Bristol Myers Squibb's anticipated schizophrenia treatment, Cobenfy, has experienced a lukewarm market entry. While meeting initial expectations in its first year, it has yet to create the breakthrough impact investors anticipated. This situation highlights the challenges even well-hyped pharmaceuticals face upon launch and underscores the need for continuous strategic planning to ensure market penetration and sustained growth.A surprising development in mergers and acquisitions comes from Novo Nordisk's $6.5 billion counteroffer to acquire Metsera, an obesity biotech initially targeted by Pfizer. This aggressive move reflects intense competition in the obesity drug market and illustrates the high stakes involved in acquiring promising biotech assets that could potentially transform treatment paradigms for chronic conditions like obesity.The vaccine industry is navigating its own set of challenges with declining sales across the board. However, Merck's adult pneumococcal vaccine Capvaxive has shown promising initial sales figures. As the first pneumococcal vaccine specifically designed for adults, Capvaxive indicates a potential niche market that Merck could successfully capture.On the regulatory front, significant measures are being taken by the FDA to boost biosimilar availability against drug pricing pressures. New draft guidance aims to eliminate clinical testing requirements for biosimilars and categorize all approved biosimilars as "interchangeable." This initiative could significantly reduce biologic medicine costs post-patent expiration and increase competition in the market, potentially making essential medications more accessible to patients. Additionally, the FDA is proposing streamlined biosimilar approval pathways aimed at reducing overall bio-drug costs—a welcome move reflecting concerted efforts to make essential medications more affordable and accessible globally.Argenx has reported positive trial results for Vyvgart in treating generalized myasthenia gravis (gMG), highlighting its commitment to addressing unmet needs within this patient population. These findings could expand treatment options for gMG patients who have been previously overlooked in thSupport the show

Carlsbergs salg af russiske Baltika Breweries var angiveligt finansieret af en tæt ven af Putin, oligarken Gennadij Timtjenko. Novo går i budkig med Pfizer for at få amerikanske Metsera - Pfizer reagerer voldsomt. Eli Lilly brager frem. ECB fastholder renten. Anders Fogh sender en kraftig advarsel om Putin. Amazon står til kæmpe kurshop.Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: https://de.scalable.capital/kinderdepot. Amazons pulverisiert Erwartungen, Apple will bestes Quartal der Firmengeschichte. Eli Lilly verlässt sich auf GLP-1 und Novo Nordisk funkt Pfizer bei Übernahme dazwischen. Ebay & Chipotle enttäuschen, Lufthansa überzeugt und Netflix splittet. Logitech (WKN: A0J3YT) legt einen Turnaround hin. Der Fokus: Keine KI, sondern Mäuse. Charismatische Gründer. Check. Milliardenumsatz. Check. Markenbekanntheit. Check. Bei Lightspeed (WKN: A3CWX3) und SumUp stimmt vieles. Bei beiden ist vieles ähnlich. Trotzdem ist SumUp zehnmal mehr wert. Was da los? Diesen Podcast vom 03.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Jim Cramer and David Faber explored what to make of earnings from three of the Magnificent 7 mega-caps: Meta shares tumbled and Microsoft's stock fell as AI spending increases overshadowed quarterly beats — while shares of Google parent Alphabet surged on better-than-expected results, fueled by strength in the cloud. Starbucks CEO Brian Niccol joined the program to discuss his company's results and turnaround plan. Eli Lilly CEO David Ricks spoke to Jim and David about his company's earnings and what's next for its Mounjaro weight loss drug. Also in focus: The meeting between Presidents Trump and Xi, Novo Nordisk-Pfizer bidding war, Chipotle plunges, Comcast's earnings message.Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC.Versant would become the new parent company of CNBC upon Comcast's planned spinoff of Versant.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

EXCLUSIVE SAVINGS FOR YOU! www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Trump said the meeting with Xi was amazing & lots of decisions were made, he rated the meeting a 12/10; US-China agree 1-year trade truce.European bourses are broadly lower, US equity futures are mixed; META -8.8%, MSFT -2.3%, GOOGL +6.9% post-earnings.JPY struggles after BoJ kept rates steady and avoided any overt hawkish commentary; Ueda said no pre-set idea about timing of next rate hike. USD manages to hold onto post-FOMC spoils.Global benchmarks (ex-JGBs) remain soft post-FOMC; EGBs pressured into the ECB.XAU returns back above USD 4k/oz following hawkish Fed cut, crude remain rangebound.Looking ahead, Looking ahead, highlights include Japanese Tokyo CPI (Oct) & Unemployment Rate (Sep), (Suspended Releases: US GDP & PCE (Q3), Weekly Claims), Events: ECB Policy Announcement, Comments from ECB President Lagarde, Fed's Logan & Bowman.Earnings from Amazon, Apple, Coinbase, Reddit, MicroStrategy, Cloudflare, Riot Platforms, Eli Lilly, Comcast, Roblox, Mastercard.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Fed cut by 25bps as expected, subject to 50bps and U/C dissent, announced it will end the balance sheet drawdown.Chair Powell struck a hawkish tone around December, weighing on stocks, USTs & XAU while the USD benefited.Trump said the meeting with Xi was amazing & lots of decisions were made, he rated the meeting a 12/10.BoJ held rates, Takata & Tamura dissented, favouring a hike; support seen in JGBs afterwards as the statement avoided any overtly hawkish signal.European futures point to a positive cash open, US futures are gradually rebounding following Powell and the first Mag 7 numbers; GOOGL +7% after-hours, MSFT -3%, META -6%Crude benchmarks faded some of the gains seen after the EIA report, XAU hit by Powell but off lows, base metals followed the risk tone.Looking ahead, highlights include Spanish Flash HICP (Oct), German Unemployment (Sep), Flash GDP (Q3), Prelim. CPI (Oct), EZ Final Consumer Confidence (Oct), Japanese Tokyo CPI (Oct) & Unemployment Rate (Sep), (Suspended Releases: US GDP & PCE (Q3), Weekly Claims), Events: ECB Policy Announcement, Comments from BoJ Governor Ueda, ECB President Lagarde, Fed's Logan & Bowman, Supply from Italy.Earnings from Amazon, Apple, Coinbase, Reddit, MicroStrategy, Cloudflare, Riot Platforms, Eli Lilly, Merck, Comcast, Roblox, Mastercard, Standard Chartered, Shell, Kion, Lufthansa, Volkswagen, Puma & ING.Click for the Newsquawk Week Ahead.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Alexis Garcia and Ed Carson analyze Thursday's market action and discuss key stocks to watch on Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of significant developments that underscore the rapid evolution within these industries.Starting with one of the major players, Merck, which has been strategically adjusting its focus in light of Keytruda's looming loss of exclusivity. The company has demonstrated remarkable progress with Welireg in kidney cancer trials, successfully pairing it with Keytruda. This combination therapy is a beacon of hope for Merck as it faces the challenges of patent expiration, highlighting the growing trend toward leveraging combination treatments to enhance efficacy in cancer therapies. This approach not only pushes the boundaries of cancer treatment but also paves the way for future therapeutic innovations. In contrast, Merck and Eisai have decided to cease their pursuit of a Keytruda-Lenvima pairing for a specific liver cancer subtype after failing to achieve overall survival benefits, despite earlier progress-free survival gains. Such developments highlight the inherent uncertainties in oncology drug development, where initial promising results may not always lead to long-term survival advantages.Meanwhile, Eli Lilly is making headlines with its substantial $1.2 billion investment to upgrade its Puerto Rico manufacturing facility. This move is aligned with their strategy to amplify production capabilities for oral drugs, particularly focusing on their promising GLP-1 pill, Orforglipron. The investment signifies a robust commitment to addressing diabetes and potentially other metabolic disorders through an expanded and more efficient production pipeline. Additionally, Eli Lilly's collaboration with NVIDIA aims at constructing an unprecedented supercomputer tailored for pharmaceutical research. This initiative leverages advanced computational power to accelerate drug discovery processes and enhance data analysis capabilities—a testament to how AI and machine learning are streamlining research workflows for developing more effective therapeutics.On the regulatory stage, Akebia Therapeutics has opted to cancel a trial for its anemia drug Vafseo after discussions with the FDA. This decision sheds light on the intricate challenges companies encounter while navigating regulatory landscapes and optimizing clinical trial strategies to ensure market success.In legal news, Kenvue is preparing for a lawsuit filed by Texas Attorney General Ken Paxton regarding alleged deceptive marketing practices about Tylenol's safety during pregnancy and its purported link to autism risk. This case emphasizes the necessity for pharmaceutical companies to uphold rigorous scientific evidence supporting their marketing claims while navigating potential legal challenges.Strategically, WuXi AppTec's decision to divest its China-based clinical research units marks a broader industry trend of streamlining operations to concentrate on core competencies. By focusing resources on its Contract Research Development and Manufacturing Organization (CRDMO) platform, WuXi aims to leverage growth opportunities in this burgeoning sector.In a notable technological partnership, Johnson & Johnson's medical technology division and Verily have entered agreements with NVIDIA, highlighting the increasing intersection of artificial intelligence with life sciences. These collaborations are poised to advance AI applications within healthcare, potentially transforming areas such as data analysis, diagnostics, and personalized medicine.The industry is also feeling the impact of governmental actions, as evidenced by a federal government shutdown starting October 1st that has led to indefinite blocks on federal worker firings. Such political developments can significantly affect healthcare funding and policymaking processes.These stories collectively paint a piSupport the show

Meta, Microsoft én Alphabet kwamen met de kwartaalcijfers en alleen de laatste werd beloond. M&M worden afgestraft voor de miljardenuitgaven in AI. Meta valt daarbij wel heel erg op: dat aandeel werd gedumpt door beleggers.Deze aflevering kijken we waarom Meta en Microsoft zó hard worden aangepakt door beleggers. Of het terecht is dat beleggers vrezen voor al die investeringen en waarom het spenderen van Alphabet wordt gedoogd.Er was ook nieuws van AEX-bedrijven. Shell had een miljard dollar meer winst dan vorig jaar, boven verwachting bovendien. Vooral de olie- en gasdivisies doen het weer beter. En, fijn voor beleggers, de marges stijgen verder. Bij ING worden er dan weer minder cadeautjes uitgedeeld aan aandeelhouders en toch stijgt het aandeel fors. Verder hoor je meer over de verpletterende cijfers van Eli Lilly én je hoort meer over de beursgang van OpenAI. Dat moet (hou je vast) duizend miljard dollar waard worden. See omnystudio.com/listener for privacy information.

Avalancha de resultados en el mercado estadounidense, con vistazo a Merck, Eli Lilly, FMC Corporation, Chipotle Mexican Grill, Apple, Amazon, Meta, Microsoft y Alphabet. Con Celso Otero, gestor de fondos de Renta 4.

#hacienda #puertorico #soborno Caen 10 personas acusadas por un Gran Jurado por un esquema de fraude en el Departamento de Hacienda que pudo haber evitado el recaudo de $3.5M en Ivu y deudas a la agencia fiscal del Estado. | Buenas noticias, la farmaceutica Eli Lilly invertirá $1,200 millones en una nueva planta para manufacturar la primera tableta "gpl1" para tratar la obesidad y la diabetes tipo 2. Se espera genera sobre 1,100 empleos desde la etapa de construcción hasta la manufactura. ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

#hacienda #puertorico #soborno Caen 10 personas acusadas por un Gran Jurado por un esquema de fraude en el Departamento de Hacienda que pudo haber evitado el recaudo de $3.5M en Ivu y deudas a la agencia fiscal del Estado. | Buenas noticias, la farmaceutica Eli Lilly invertirá $1,200 millones en una nueva planta para manufacturar la primera tableta "gpl1" para tratar la obesidad y la diabetes tipo 2. Se espera genera sobre 1,100 empleos desde la etapa de construcción hasta la manufactura. ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

Terwijl Nederland wachtte op de exitpolls, zat de échte spanning vandaag op de beursvloer. Beleggers stuwden één bedrijf naar een recordwaarde: Nvidia. De chipmaker tikte als eerste in de geschiedenis een beurswaarde van 5000 miljard dollar aan. Wat kun je eigenlijk met dat bedrag? Rens en Jochem rekenden het uit. Spoiler: je kan de aarde rond met een treintje van de nieuwste Ferrari Testarossa Spiders. Het record van Nvidia komt trouwens niet uit de lucht vallen. De chipgigant profiteert van een spervuur aan deals: van samenwerkingen met Nokia tot een partnership met farmareus Eli Lilly. Zelfs Donald Trump mengde zich in het feestgedruis. Hij is trots dat Nvidia’s snelste chips nu in Arizona gemaakt gaan worden in plaats van in Taiwan. De vraag is natuurlijk wel: hoe lang kan dit groeiverhaal nog doorgaan? Op het Damrak was een glansrol weggelegd voor Adyen. Het betaalbedrijf steeg met 5 procent na sterke kwartaalcijfers. De omzet groeide met 20 procent naar bijna 600 miljoen euro, en door de systemen van Adyen stroomde in drie maanden tijd 350 miljard euro. Bedenk je even: per jaar gaat er meer door de systemen van Adyen dan door de Nederlandse economie. Vooral het onderdeel Unified Commerce, dat online en fysieke betalingen samenbrengt, maakte indruk met 32 procent groei. Ook ASM kwam met cijfers. De chipmachinefabrikant zag het aantal orders uit China dalen, maar hield de vooruitzichten positief. De top van het bedrijf verwacht de komende jaren stevige groei dankzij de vraag naar AI- en geheugenchips. Maar daar moet je wel even op wachten. Pas op de lange termijn belooft ASM cadeautjes voor beleggers: een verdubbeling van omzet en kasstroom richting 2030. En alsof dat nog niet genoeg was, dook er ook een nieuwe uitdager op voor ASML én TSMC: de Amerikaanse start-up Substrate, gesteund door investeerder Peter Thiel. Het bedrijf zegt een compleet nieuwe manier te hebben ontwikkeld om chips te maken. Beter, sneller en goedkoper. Of dat echt zo is, of dat de bollebozen bij ASML hun schouders ophalen, blijft nog even de vraag. Maar de techstrijd is nog lang niet gestreden.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic maneuvers reshaping the industry.BioMarin's recent decision to divest from its hemophilia A gene therapy, Roctavian, has garnered significant attention. Despite being the sole approved gene therapy for hemophilia A, Roctavian has struggled with sales since its launch two years ago. This move underscores the complex challenges in commercializing gene therapies, highlighting that even groundbreaking treatments can face hurdles in market penetration. It reflects broader implications for the commercialization strategies of innovative therapies and emphasizes that market acceptance is as crucial as clinical efficacy.In manufacturing and regulatory affairs, Regeneron is navigating hurdles with its Eylea HD due to persistent manufacturing issues. The FDA's complete response letter points to ongoing problems at a Novo Nordisk plant. This situation illustrates the critical role of manufacturing standards in securing regulatory approvals and ensuring consistent product availability. Regeneron's efforts to seek alternative manufacturing solutions emphasize the importance of compliance and quality assurance in the pharmaceutical landscape.Roche is advancing its kidney disease portfolio with a Phase 3 trial success for Gazyva against idiopathic nephrotic syndrome. Building on previous approvals for lupus nephritis, this achievement underscores Roche's strategic focus on expanding indications for existing biologics. It highlights the value of lifecycle management strategies in maximizing therapeutic potentials and extending the reach of established drugs.A significant shift in pharmacy benefit management is underway as Cigna's Evernorth division moves away from PBM rebates through Express Scripts. This transition towards a rebate-free model may influence industry-wide practices, addressing growing scrutiny over rebate structures criticized for their lack of transparency and their impact on drug pricing.CSL's decision to delay the spinoff of its flu vaccine unit amid declining U.S. immunization rates illustrates market challenges in vaccine uptake. The anticipated drop, particularly among older populations, raises public health concerns and underscores the necessity for enhanced outreach and education to improve immunization coverage.On the investment front, AbbVie, Regeneron, and Sanofi have collectively invested $80 million in ZAG Bio's Series A funding round. This company is developing thymus-targeted medicines for autoimmune diseases, reflecting continued interest in novel therapeutic approaches addressing unmet medical needs within the biotech space.Catalent's rebranding initiative signifies a strategic effort to align corporate identity with mission-driven objectives, emphasizing "missions that matter" as it approaches an anniversary milestone with Novo Nordisk's acquisition. Such rebranding efforts are critical for differentiating service offerings and reinforcing corporate values within competitive markets.The competitive landscape within diabetes and obesity treatment markets is experiencing a potential paradigm shift following the results from Innovent and Eli Lilly's Phase 3 trial of mazdutide. This dual GLP-1/glucagon receptor agonist outperformed Novo Nordisk's semaglutide, offering improved outcomes in weight reduction and glycemic control. Mazdutide's dual mechanism could redefine treatment protocols, offering patients enhanced therapeutic benefits.MapLight Therapeutics has successfully raised $250 million through an IPO to advance its schizophrenia treatment candidate, Cobenfy. This funding supports further clinical development and potential commercialization efforts, reflecting investor confidence in innovative neurologSupport the show

#hacienda #puertorico #soborno Caen 10 personas acusadas por un Gran Jurado por un esquema de fraude en el Departamento de Hacienda que pudo haber evitado el recaudo de $3.5M en Ivu y deudas a la agencia fiscal del Estado. | Buenas noticias, la farmaceutica Eli Lilly invertirá $1,200 millones en una nueva planta para manufacturar la primera tableta "gpl1" para tratar la obesidad y la diabetes tipo 2. Se espera genera sobre 1,100 empleos desde la etapa de construcción hasta la manufactura. ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

#hacienda #puertorico #soborno Caen 10 personas acusadas por un Gran Jurado por un esquema de fraude en el Departamento de Hacienda que pudo haber evitado el recaudo de $3.5M en Ivu y deudas a la agencia fiscal del Estado. | Buenas noticias, la farmaceutica Eli Lilly invertirá $1,200 millones en una nueva planta para manufacturar la primera tableta "gpl1" para tratar la obesidad y la diabetes tipo 2. Se espera genera sobre 1,100 empleos desde la etapa de construcción hasta la manufactura. ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

Plus: Nvidia unveils a new product that merges AI supercomputing with quantum. And the AI giant partners with Eli Lilly to build a supercomputer that could boost drug discovery. Julie Chang hosts. Correction: OpenAI's nonprofit parent owns a stake in its for-profit subsidiary, which has become a public-benefit corporation. An earlier version of this podcast incorrectly said OpenAI had become a for-profit company. (Corrected Oct. 28) Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show

Show Notes:In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable WegovyHow orforglipron, Eli Lilly's new small-molecule GLP-1, differs from peptide-based drugsWhy these new therapies could make weight management more accessible and affordableThe fascinating pharmacology behind “snack molecules” and small-molecule receptor agonistsCommon misconceptions about bioavailability, dosing, and side effectsThe potential role of oral GLP-1s for patients with mild obesity or cardiometabolic diseaseWhether you're a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.Oasis 1 Trial LinkOasis 4 Trial LinkAttain 1 Trial Link Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.